Bayer

Bayer’s Pivotal Quarter: Legal Battles and Leadership Shifts Shape the Path Forward

Brett Shapiro - April 11, 2026

Trade Tensions Cast Shadow Over Bayer’s Pharmaceutical Ambitions

kashif hafeez - April 6, 2026

FDA Approval of Lynkuet Marks Strategic Milestone for Bayer

Brett Shapiro - March 29, 2026

Analysts Shift to Bullish Stance on Bayer Shares

March 17, 2026

Bayer’s Oncology Ambitions: Darolutamid Study Targets Earlier Prostate Cancer Treatment

March 9, 2026

Bayer’s Financial Outlook Dimmed by Legal Liabilities

angelina - March 5, 2026

Legal Delays Threaten Bayer’s Settlement Strategy

kashif hafeez - February 28, 2026